Long-distance Retrograde Effects of Botulinum Neurotoxin A

Overview

Journal J Neurosci

Specialty Neurology

Date 2008 Apr 4

PMID 18385327

Citations 161

Authors

Flavia Antonucci

Chiara Rossi

Laura Gianfranceschi

Ornella Rossetto

Matteo Caleo

Affiliations

Soon will be listed here.

Abstract

Botulinum neurotoxins (designated BoNT/A-BoNT/G) are bacterial enzymes that block neurotransmitter release by cleaving essential components of the vesicle fusion machinery. BoNT/A, which cleaves SNAP-25 (synaptosomal-associated protein of 25 kDa), is extensively exploited in clinical medicine to treat neuromuscular pathologies, facial wrinkles, and various types of pain. It is widely assumed that BoNT/A remains at the synaptic terminal and its effects are confined to the injection site. Here we demonstrate that catalytically active BoNT/A is retrogradely transported by central neurons and motoneurons and is then transcytosed to afferent synapses, in which it cleaves SNAP-25. SNAP-25 cleavage by BoNT/A was observed in the contralateral hemisphere after unilateral BoNT/A delivery to the hippocampus. Appearance of cleaved SNAP-25 resulted in blockade of hippocampal activity in the untreated hemisphere. Injections of BoNT/A into the optic tectum led to the appearance of BoNT/A-truncated SNAP-25 in synaptic terminals within the retina. Cleaved SNAP-25 also appeared in the facial nucleus after injection of the toxin into rat whisker muscles. Experiments excluded passive spread of the toxin and demonstrated axonal migration and neuronal transcytosis of BoNT/A. These findings reveal a novel pathway of BoNT/A trafficking in neurons and have important implications for the clinical uses of this neurotoxin.

Citing Articles

Pioneering pain management with botulinum toxin type A: From anti-inflammation to regenerative therapies.

Rahmatipour H, Shabestari S, Benisi S, Samadikhah H Heliyon. 2025; 11(4):e42350.

PMID: 40028584 PMC: 11870196. DOI: 10.1016/j.heliyon.2025.e42350.

Botulinum Toxin: A Comprehensive Review of Its Molecular Architecture and Mechanistic Action.

Kumar R, Singh B Int J Mol Sci. 2025; 26(2).

PMID: 39859491 PMC: 11766063. DOI: 10.3390/ijms26020777.

The Esthetic Use of Botulinum Toxins in Cancer Patients: Providing a Foundation for Future Indications.

Papagni M, Renga M, Mogavero S, Veronesi P, Cavallini M Toxins (Basel). 2025; 17(1).

PMID: 39852984 PMC: 11769536. DOI: 10.3390/toxins17010031.

Scoping Review: The Effects of Interrupted Onabotulinumtoxin A Treatment for Chronic Migraine Prevention During the COVID-19 Pandemic.

Ruan Q, Pak D, Gulati A, Dominguez M, Diwan S, Hasoon J J Pain Res. 2024; 17:4163-4176.

PMID: 39679430 PMC: 11645906. DOI: 10.2147/JPR.S485548.

Memory-Guided Saccades and Non-Motor Symptoms Improve after Botulinum Toxin Therapy in Cervical Dystonia.

Gilman Kuric T, Popovic Z, Matosa S, Sadikov A, Groznik V, Georgiev D J Clin Med. 2024; 13(19).

PMID: 39407768 PMC: 11477116. DOI: 10.3390/jcm13195708.

References

Foster K, Bigalke H, Aoki K . Botulinum neurotoxin - from laboratory to bedside. Neurotox Res. 2006; 9(2-3):133-40. DOI: 10.1007/BF03033931. View

Montecucco C, Schiavo G, Pantano S . SNARE complexes and neuroexocytosis: how many, how close?. Trends Biochem Sci. 2005; 30(7):367-72. DOI: 10.1016/j.tibs.2005.05.002. View

Mahrhold S, Rummel A, Bigalke H, Davletov B, Binz T . The synaptic vesicle protein 2C mediates the uptake of botulinum neurotoxin A into phrenic nerves. FEBS Lett. 2006; 580(8):2011-4. DOI: 10.1016/j.febslet.2006.02.074. View

Verderio C, Rossetto O, Grumelli C, Frassoni C, Montecucco C, Matteoli M . Entering neurons: botulinum toxins and synaptic vesicle recycling. EMBO Rep. 2006; 7(10):995-9. PMC: 1618376. DOI: 10.1038/sj.embor.7400796. View

Kanovsky P, Streitova H, Dufek J, Znojil V, Daniel P, Rektor I . Change in lateralization of the P22/N30 cortical component of median nerve somatosensory evoked potentials in patients with cervical dystonia after successful treatment with botulinum toxin A. Mov Disord. 1998; 13(1):108-17. DOI: 10.1002/mds.870130122. View

Franchi G . Time course of motor cortex reorganization following botulinum toxin injection into the vibrissal pad of the adult rat. Eur J Neurosci. 2002; 16(7):1333-48. DOI: 10.1046/j.1460-9568.2002.02195.x. View

Garner C, Straube A, Witt T, Gasser T, Oertel W . Time course of distant effects of local injections of botulinum toxin. Mov Disord. 1993; 8(1):33-7. DOI: 10.1002/mds.870080106. View

Wiegand H, Erdmann G, WELLHONER H . 125I-labelled botulinum A neurotoxin: pharmacokinetics in cats after intramuscular injection. Naunyn Schmiedebergs Arch Pharmacol. 1976; 292(2):161-5. DOI: 10.1007/BF00498587. View

Deinhardt K, Berninghausen O, Willison H, Hopkins C, Schiavo G . Tetanus toxin is internalized by a sequential clathrin-dependent mechanism initiated within lipid microdomains and independent of epsin1. J Cell Biol. 2006; 174(3):459-71. PMC: 2064241. DOI: 10.1083/jcb.200508170. View

10.

Sudhof T . The synaptic vesicle cycle. Annu Rev Neurosci. 2004; 27:509-47. DOI: 10.1146/annurev.neuro.26.041002.131412. View

11.

Wohlfarth K, Schubert M, ROTHE B, Elek J, Dengler R . Remote F-wave changes after local botulinum toxin application. Clin Neurophysiol. 2001; 112(4):636-40. DOI: 10.1016/s1388-2457(01)00478-3. View

12.

Lalli G, Bohnert S, Deinhardt K, Verastegui C, Schiavo G . The journey of tetanus and botulinum neurotoxins in neurons. Trends Microbiol. 2003; 11(9):431-7. DOI: 10.1016/s0966-842x(03)00210-5. View

13.

Costantin L, Bozzi Y, Richichi C, Viegi A, Antonucci F, Funicello M . Antiepileptic effects of botulinum neurotoxin E. J Neurosci. 2005; 25(8):1943-51. PMC: 6726074. DOI: 10.1523/JNEUROSCI.4402-04.2005. View

14.

Schiavo G, Matteoli M, Montecucco C . Neurotoxins affecting neuroexocytosis. Physiol Rev. 2000; 80(2):717-66. DOI: 10.1152/physrev.2000.80.2.717. View

15.

Schwab M, Suda K, Thoenen H . Selective retrograde transsynaptic transfer of a protein, tetanus toxin, subsequent to its retrograde axonal transport. J Cell Biol. 1979; 82(3):798-810. PMC: 2110489. DOI: 10.1083/jcb.82.3.798. View

16.

von Bartheld C . Axonal transport and neuronal transcytosis of trophic factors, tracers, and pathogens. J Neurobiol. 2004; 58(2):295-314. DOI: 10.1002/neu.10315. View

17.

Gilio F, Curra A, Lorenzano C, Modugno N, Manfredi M, Berardelli A . Effects of botulinum toxin type A on intracortical inhibition in patients with dystonia. Ann Neurol. 2000; 48(1):20-6. View

18.

Priori A, Berardelli A, Mercuri B, Manfredi M . Physiological effects produced by botulinum toxin treatment of upper limb dystonia. Changes in reciprocal inhibition between forearm muscles. Brain. 1995; 118 ( Pt 3):801-7. DOI: 10.1093/brain/118.3.801. View

19.

Habermann E . 125I-labeled neurotoxin from Clostridium botulinum A: preparation, binding to synaptosomes and ascent to the spinal cord. Naunyn Schmiedebergs Arch Pharmacol. 1974; 281(1):47-56. DOI: 10.1007/BF00500611. View

20.

Dong M, Yeh F, Tepp W, Dean C, Johnson E, Janz R . SV2 is the protein receptor for botulinum neurotoxin A. Science. 2006; 312(5773):592-6. DOI: 10.1126/science.1123654. View